Business Context and Reporting Period
This Form 6-K filing by SciSparc Ltd. covers the month of July 2026, with a specific report date of July 15, 2026. The filing serves to distribute a press release regarding a strategic partnership with NeuroThera Labs.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes
The primary material event disclosed is the initiation of a Phase IIb clinical trial for an innovative treatment of Tourette Syndrome. The trial is being conducted at Hannover Medical School in Germany by NeuroThera Labs.
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward-Looking Statements" section from the accompanying press release (Exhibit 99.1). The document notes that the press release content is incorporated into the Company's registration statements on Form F-3 and Form S-8. No specific numerical guidance or detailed risk factors are enumerated within the body of this Form 6-K text.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the Phase IIb trial design and endpoints.
- Review the "Forward-Looking Statements" section in the press release for specific risks associated with the clinical trial.
- Confirm the nature of the collaboration agreement between SciSparc Ltd. and NeuroThera Labs.
- Check subsequent filings for any updates on the trial's progress or financial impact.